Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 3/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196503 | 0.89 | MEN1 (0.39) | MEN1KMT2ATLR2 | |
| SCHEMBL12196496 | 0.87 | MEN1 (0.36) | MEN1KMT2ATLR2 | |
| SCHEMBL15256876 | 0.86 | EPHX2 (0.36) | MEN1KMT2ANAAA | |
| SCHEMBL15256893 | 0.81 | SIRT6 (0.42) | TLR2 | |
| SCHEMBL12706033 | 0.72 | MEN1 (0.34) | MEN1KMT2ATLR2 | |
| SCHEMBL8396346 | 0.71 | EPHX1 (0.52) | MEN1KMT2AEPHX1 | |
| SCHEMBL12706048 | 0.68 | MEN1 (0.38) | MEN1KMT2AEPHX1TLR2 | |
| SCHEMBL12705941 | 0.68 | EPHX1 (0.50) | MEN1KMT2AEPHX1TLR2 | |
| SCHEMBL8397010 | 0.68 | EPHX1 (0.45) | EPHX1 | |
| SCHEMBL9340071 | 0.67 | EPHX1 (0.52) | MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729030-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | AFFYMAX, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3831/4885KMT2A 4517/4885NAAA 4650/4885 |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3831/4885KMT2A 4517/4885NAAA 4650/4885 |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | EPOR, MPL, PROKR1 | MEN1 1252/4885KMT2A 3761/4885NAAA 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.